title: The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.
abstract: OBJECTIVE
  To review the predictive values of Ki-67 before neoadjuvant chemotherapy (NAC) for breast cancer patients.
  
  
  METHODS
  PubMed and EMBASE were searched. Random-effect model meta-analysis was conducted using Revman software.
  
  
  RESULTS
  High Ki-67 was associated with more pathological complete responses (pCRs) events (odds ratio: 3.10; 95% CI: 2.52-3.81; 53 studies, 10,848 patients) regardless of HR+, HER2+and triple-negative breast cancer types, the definitions of pCR and cut-off points for Ki-67. Ki-67 could predict pCR in those who received anthracyclines plus taxanes, and anthracyclines only, and those from Asia and Europe.
  
  
  CONCLUSIONS
  High Ki-67 before NAC was a predictor for pCR in neoadjuvant setting for breast cancer patients.
authors.affiliation: Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
authors.forename: Xianyu
authors.initials: X
authors.lastname: Chen
authors.affiliation: Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
authors.forename: Chao
authors.initials: C
authors.lastname: He
authors.affiliation: Department of Urology, the Second Hospital of Lanzhou University, Lanzhou, China.
authors.forename: Dongdong
authors.initials: D
authors.lastname: Han
authors.affiliation: Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
authors.forename: Meirong
authors.initials: M
authors.lastname: Zhou
authors.affiliation: Department of Gastrointestinal Surgery, Xijing Hospital of Digestive Diseases, Xijing Hospital, Four Military Medical University, Xi'an, Shaanxi, China.
authors.forename: Quan
authors.initials: Q
authors.lastname: Wang
authors.affiliation: Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
authors.forename: Jinhui
authors.initials: J
authors.lastname: Tian
authors.affiliation: Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
authors.forename: Lun
authors.initials: L
authors.lastname: Li
authors.affiliation: Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Xu
authors.affiliation: Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
authors.forename: Enxiang
authors.initials: E
authors.lastname: Zhou
authors.affiliation: Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
authors.forename: Kehu
authors.initials: K
authors.lastname: Yang
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism*; D020360:Neoadjuvant Therapy; D016017:Odds Ratio; D011379:Prognosis; D017594:Publication Bias; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen
keywords: Ki-67; neoadjuvant chemotherapy; pathological complete response